Skip to main content

Table 3 Risk of colorectal cancer and molecular subgroups in relation to HRT and ERT use

From: Associations of hormone replacement therapy and oral contraceptives with risk of colorectal cancer defined by clinicopathological factors, beta-catenin alterations, expression of cyclin D1, p53, and microsatellite-instability

Tumour subgroups HRT use n HR crude p HR adjusted p
beta-catenin + No 126 1.00   1.00  
ERT 13 0.93(0.52-1.64) 0.790 1.04(0.58-1.84) 0.902
CHRT 19 0.64(0.40-1.04) 0.074 0.87(0.53-1.42) 0.868
beta-catenin − No 80 1.00   1.00  
ERT 7 0.76(0.35-1.65) 0.490 0.77(0.36-1.68) 0.516
CHRT 13 0.69(0.39-1.24) 0.217 0.83(0.46-1.50) 0.533
cyclin D1 + No 173 1.00   1.00  
ERT 16 0.81(0.49-1.35) 0.416 0.87(0.52-145) 0.591
CHRT 29 0.72(0.48-1.06) 0.096 0.93(0.63-1.39) 0.734
cyclin D1 − No 31 1.00   1.00  
ERT 4 1.16(0.41-3.28) 0.782 1.26(0.44-3.59) 0.661
CHRT 5 0.68(0.27-1.75) 0.425 0.84(0.32-2.19) 0.721
p53 + No 99 1.00   1.00  
ERT 11 0.98(0.53-1.83) 0.956 1.07(0.57-1.99) 0.843
CHRT 18 0.78(0.47-1.29) 0.334 1.00(0.59-1.65) 0.970
p53 − No 107 1.00   1.00  
ERT 9 0.74(0.37-1.45) 0.374 0.79(0.40-1.55) 0.488
CHRT 16 0.63(0.38-1.07) 0.089 0.84(0.49-1.42) 0.508
MSI No 38 1.00   1.00  
ERT 1 0.23(0.03-1.63) 0.140 0.24(0.03-1.72) 0.154
CHRT 5 0.56(0.22-1.43) 0.225 0.80(0.31-2.06) 0.649
MSS No 164 1.00   1.00  
ERT 18 0.97(0.60-1.58) 0.903 1.06(0.65-1.72) 0.829
CHRT 28 0.73(0.49-1.09) 0.120 0.92(0.61-1.39) 0.700
  1. Adjusted for age, bmi, educational level, smoking habits and alcohol consumption.